- Report
- May 2026
- 276 Pages
Global
From €5135EUR$5,850USD£4,441GBP
- Report
- May 2026
- 150 Pages
Global
From €5135EUR$5,850USD£4,441GBP
- Report
- May 2026
- 142 Pages
Global
From €5135EUR$5,850USD£4,441GBP
- Report
- May 2026
- 181 Pages
Global
From €5135EUR$5,850USD£4,441GBP
- Report
- May 2026
- 349 Pages
Global
From €5135EUR$5,850USD£4,441GBP
- Report
- May 2026
- 193 Pages
Global
From €5135EUR$5,850USD£4,441GBP
- Report
- May 2026
- 504 Pages
Global
From €5135EUR$5,850USD£4,441GBP
- Report
- May 2026
- 263 Pages
Global
From €5135EUR$5,850USD£4,441GBP
- Report
- May 2026
- 193 Pages
Global
From €5135EUR$5,850USD£4,441GBP
- Report
- February 2026
- 250 Pages
Global
From €3941EUR$4,490USD£3,409GBP
- Report
- January 2026
- 450 Pages
Global
From €4389EUR$5,000USD£3,796GBP
- Report
- November 2025
- 200 Pages
Global
From €6978EUR$7,950USD£6,035GBP
- Report
- May 2026
- 177 Pages
Global
From €3950EUR$4,500USD£3,416GBP
- Report
- January 2026
- 186 Pages
Global
From €3950EUR$4,500USD£3,416GBP
- Report
- November 2025
- 190 Pages
Global
From €3950EUR$4,500USD£3,416GBP
- Report
- September 2025
- 185 Pages
Global
From €3950EUR$4,500USD£3,416GBP
- Report
- June 2025
- 185 Pages
Global
From €3950EUR$4,500USD£3,416GBP
- Report
- January 2026
- 180 Pages
Global
From €2633EUR$3,000USD£2,277GBP
- Report
- June 2025
- 150 Pages
Global
From €2369EUR$2,699USD£2,049GBP
- Report
- June 2025
- 150 Pages
Global
From €2369EUR$2,699USD£2,049GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more